Shanghai Meiyue Biotech Development Co. Ltd. has synthesized new benzopyrimidine compounds acting as histone-lysine N -methyltransferase EHMT2 (H3-K9-HMTase 3; G9a) inhibitors potentially useful for the treatment of cancer, autoimmune disease, metabolic diseases, gastrointestinal and inflammatory disorders.